HELP Helus Pharma
Helus Pharma (HELP) is expected to report earnings on February 12, 2027, before the market open. The consensus earnings estimate is a loss of $0.68 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -24.7% since its last earnings release on November 13, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Helus Pharma
Helus Pharma is a clinical stage pharmaceutical company. Its lead candidate includes HLP003 and HLP004. Helus Pharma, formerly known as Cybin Inc., is based in BOSTON.
Sector
Healthcare
Industry
Drug Manufacturers/Other
Charts powered in part by Lightweight Charts™ by TradingView.